Switch to:
Also traded in: Australia, Germany, USA

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 5/10

vs
industry
vs
history
Cash-to-Debt No Debt
MEOBF's Cash-to-Debt is ranked higher than
91% of the 962 Companies
in the Global Biotechnology industry.

( Industry Median: 59.90 vs. MEOBF: No Debt )
Ranked among companies with meaningful Cash-to-Debt only.
MEOBF' s Cash-to-Debt Range Over the Past 10 Years
Min: N/A  Med: N/A Max: No Debt
Current: No Debt
N/A
No Debt
Equity-to-Asset 0.77
MEOBF's Equity-to-Asset is ranked higher than
62% of the 715 Companies
in the Global Biotechnology industry.

( Industry Median: 0.67 vs. MEOBF: 0.77 )
Ranked among companies with meaningful Equity-to-Asset only.
MEOBF' s Equity-to-Asset Range Over the Past 10 Years
Min: 0.6  Med: 0.62 Max: 0.77
Current: 0.77
0.6
0.77
Altman Z-Score: 0.81
WACC vs ROIC
12.98%
-32.92%
WACC
ROIC
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 1/10

vs
industry
vs
history
Operating Margin % -77.90
MEOBF's Operating Margin % is ranked higher than
51% of the 743 Companies
in the Global Biotechnology industry.

( Industry Median: -88.13 vs. MEOBF: -77.90 )
Ranked among companies with meaningful Operating Margin % only.
MEOBF' s Operating Margin % Range Over the Past 10 Years
Min: -1357.78  Med: -361.62 Max: 77.57
Current: -77.9
-1357.78
77.57
Net Margin % -29.68
MEOBF's Net Margin % is ranked higher than
59% of the 743 Companies
in the Global Biotechnology industry.

( Industry Median: -75.28 vs. MEOBF: -29.68 )
Ranked among companies with meaningful Net Margin % only.
MEOBF' s Net Margin % Range Over the Past 10 Years
Min: -1932.16  Med: -404.99 Max: 74.96
Current: -29.68
-1932.16
74.96
ROE % -2.63
MEOBF's ROE % is ranked higher than
74% of the 874 Companies
in the Global Biotechnology industry.

( Industry Median: -34.32 vs. MEOBF: -2.63 )
Ranked among companies with meaningful ROE % only.
MEOBF' s ROE % Range Over the Past 10 Years
Min: -51.29  Med: -17.63 Max: 32.19
Current: -2.63
-51.29
32.19
ROA % -1.81
MEOBF's ROA % is ranked higher than
76% of the 972 Companies
in the Global Biotechnology industry.

( Industry Median: -30.23 vs. MEOBF: -1.81 )
Ranked among companies with meaningful ROA % only.
MEOBF' s ROA % Range Over the Past 10 Years
Min: -48.74  Med: -11.27 Max: 22.31
Current: -1.81
-48.74
22.31
ROC (Joel Greenblatt) % -3350.43
MEOBF's ROC (Joel Greenblatt) % is ranked lower than
76% of the 925 Companies
in the Global Biotechnology industry.

( Industry Median: -407.53 vs. MEOBF: -3350.43 )
Ranked among companies with meaningful ROC (Joel Greenblatt) % only.
MEOBF' s ROC (Joel Greenblatt) % Range Over the Past 10 Years
Min: -6969.16  Med: -3187.57 Max: 20767.8
Current: -3350.43
-6969.16
20767.8
3-Year Revenue Growth Rate 8.60
MEOBF's 3-Year Revenue Growth Rate is ranked higher than
58% of the 480 Companies
in the Global Biotechnology industry.

( Industry Median: 4.20 vs. MEOBF: 8.60 )
Ranked among companies with meaningful 3-Year Revenue Growth Rate only.
MEOBF' s 3-Year Revenue Growth Rate Range Over the Past 10 Years
Min: -46.2  Med: -3.9 Max: 296.9
Current: 8.6
-46.2
296.9
3-Year EBITDA Growth Rate 11.70
MEOBF's 3-Year EBITDA Growth Rate is ranked higher than
64% of the 521 Companies
in the Global Biotechnology industry.

( Industry Median: 1.70 vs. MEOBF: 11.70 )
Ranked among companies with meaningful 3-Year EBITDA Growth Rate only.
MEOBF' s 3-Year EBITDA Growth Rate Range Over the Past 10 Years
Min: -7.6  Med: 20.4 Max: 44.2
Current: 11.7
-7.6
44.2
3-Year EPS without NRI Growth Rate -59.50
MEOBF's 3-Year EPS without NRI Growth Rate is ranked lower than
94% of the 507 Companies
in the Global Biotechnology industry.

( Industry Median: -3.10 vs. MEOBF: -59.50 )
Ranked among companies with meaningful 3-Year EPS without NRI Growth Rate only.
MEOBF' s 3-Year EPS without NRI Growth Rate Range Over the Past 10 Years
Min: -59.5  Med: 15.5 Max: 50
Current: -59.5
-59.5
50
GuruFocus has detected 1 Warning Sign with Mesoblast Ltd $MEOBF.
More than 500,000 people have already joined GuruFocus to track the stocks they follow and exchange investment ideas.
» MEOBF's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Operating Cash Flow & Free Cash Flow
Operating Cash Flow & Net Income

» Details

Insider Trades

Latest Guru Trades with MEOBF

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Business Description

Industry: Biotechnology » Biotechnology    NAICS: 541711 
Compare:OTCPK:ABVC, NAS:NVAX, NAS:PTI, NAS:MACK, NAS:AVDL, NAS:CARA, NAS:TLGT, NAS:NSTG, NAS:NK, NAS:CTMX, NAS:MYOK, NAS:RXDX, NAS:CLDX, NAS:AKBA, NAS:XBIT, NAS:TRVN, NAS:CRBP, NAS:AGEN, NAS:CERS, NAS:MRUS » details
Traded in other countries:MSB.Australia, LWB.Germany, MESO.USA,
Mesoblast Ltd is engaged in the development of regenerative medicine products. The Company's proprietary regenerative medicine technology platform is based on specialized cells known as mesenchymal lineage adult stem cells.

Mesoblast Ltd is an Australian biotechnology company formed in 2004. The Company is engaged in the development, manufacturing and commercialization of biological products for the field of regenerative medicine. Its products are for cardiovascular conditions, diabetes, inflammatory conditions of lungs and joints, eye diseases, bone marrow cancers, bone fractures, cartilage degeneration and musculoskeletal conditions. The Company and Teva Pharmaceutical Industries Ltd., have established a strategic alliance to commercialize adult stem cell products for degenerative conditions of the cardiovascular and central nervous systems. The alliance also extends to products for augmenting bone marrow transplantation in cancer patients.

Ratios

vs
industry
vs
history
PB Ratio 0.91
MEOBF's PB Ratio is ranked higher than
92% of the 1106 Companies
in the Global Biotechnology industry.

( Industry Median: 3.65 vs. MEOBF: 0.91 )
Ranked among companies with meaningful PB Ratio only.
MEOBF' s PB Ratio Range Over the Past 10 Years
Min: 0.57  Med: 0.91 Max: 2.24
Current: 0.91
0.57
2.24
PS Ratio 12.11
MEOBF's PS Ratio is ranked higher than
51% of the 853 Companies
in the Global Biotechnology industry.

( Industry Median: 12.50 vs. MEOBF: 12.11 )
Ranked among companies with meaningful PS Ratio only.
MEOBF' s PS Ratio Range Over the Past 10 Years
Min: 6.46  Med: 28.51 Max: 261.18
Current: 12.11
6.46
261.18
Current Ratio 2.26
MEOBF's Current Ratio is ranked lower than
71% of the 950 Companies
in the Global Biotechnology industry.

( Industry Median: 4.13 vs. MEOBF: 2.26 )
Ranked among companies with meaningful Current Ratio only.
MEOBF' s Current Ratio Range Over the Past 10 Years
Min: 2.26  Med: 3.1 Max: 6.56
Current: 2.26
2.26
6.56
Quick Ratio 2.26
MEOBF's Quick Ratio is ranked lower than
68% of the 948 Companies
in the Global Biotechnology industry.

( Industry Median: 3.91 vs. MEOBF: 2.26 )
Ranked among companies with meaningful Quick Ratio only.
MEOBF' s Quick Ratio Range Over the Past 10 Years
Min: 2.26  Med: 3.1 Max: 6.56
Current: 2.26
2.26
6.56
Days Sales Outstanding 3.61
MEOBF's Days Sales Outstanding is ranked higher than
94% of the 592 Companies
in the Global Biotechnology industry.

( Industry Median: 62.87 vs. MEOBF: 3.61 )
Ranked among companies with meaningful Days Sales Outstanding only.
MEOBF' s Days Sales Outstanding Range Over the Past 10 Years
Min: 0.07  Med: 4.27 Max: 110.87
Current: 3.61
0.07
110.87

Buy Back

vs
industry
vs
history
3-Year Average Share Buyback Ratio -8.90
MEOBF's 3-Year Average Share Buyback Ratio is ranked higher than
56% of the 556 Companies
in the Global Biotechnology industry.

( Industry Median: -10.90 vs. MEOBF: -8.90 )
Ranked among companies with meaningful 3-Year Average Share Buyback Ratio only.
MEOBF' s 3-Year Average Share Buyback Ratio Range Over the Past 10 Years
Min: -27.6  Med: -13.3 Max: -5.6
Current: -8.9
-27.6
-5.6

Valuation & Return

vs
industry
vs
history
Price-to-Intrinsic-Value-Projected-FCF 5.50
MEOBF's Price-to-Intrinsic-Value-Projected-FCF is ranked lower than
99.99% of the 174 Companies
in the Global Biotechnology industry.

( Industry Median: 3.31 vs. MEOBF: 5.50 )
Ranked among companies with meaningful Price-to-Intrinsic-Value-Projected-FCF only.
MEOBF' s Price-to-Intrinsic-Value-Projected-FCF Range Over the Past 10 Years
Min: 0  Med: 0 Max: 5.5
Current: 5.5
0
5.5
Price-to-Median-PS-Value 0.42
MEOBF's Price-to-Median-PS-Value is ranked higher than
84% of the 765 Companies
in the Global Biotechnology industry.

( Industry Median: 0.97 vs. MEOBF: 0.42 )
Ranked among companies with meaningful Price-to-Median-PS-Value only.
MEOBF' s Price-to-Median-PS-Value Range Over the Past 10 Years
Min: 0.23  Med: 1.23 Max: 9.15
Current: 0.42
0.23
9.15
Earnings Yield (Greenblatt) % -22.50
MEOBF's Earnings Yield (Greenblatt) % is ranked lower than
71% of the 1203 Companies
in the Global Biotechnology industry.

( Industry Median: -9.03 vs. MEOBF: -22.50 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) % only.
MEOBF' s Earnings Yield (Greenblatt) % Range Over the Past 10 Years
Min: -69.25  Med: 5.8 Max: 7.2
Current: -22.5
-69.25
7.2

More Statistics

Revenue (TTM) (Mil) $35.43
EPS (TTM) $ -5.21
Beta3.08
Short Percentage of Float0.00%
52-Week Range $0.70 - 2.05
Shares Outstanding (Mil)378.15

Analyst Estimate

Jun17 Jun18 Jun19
Revenue (Mil $) 7 10 17
EPS ($) -0.18 -0.15 -0.16
EPS without NRI ($) -0.18 -0.15 -0.16
EPS Growth Rate
(Future 3Y To 5Y Estimate)
N/A
Dividends per Share ($)
» More Articles for MEOBF

Headlines

Articles On GuruFocus.com
Big Pharma Companies Are Betting On Regenerative Medicine - Should You? May 26 2015 

More From Other Websites
Mallinckrodt enters $21 million equity purchase agreement with Mesoblast Dec 23 2016
Mesoblast And Mallinckrodt Enter Into Agreement Dec 22 2016
Results of Meeting Nov 22 2016
CEO Presentation to 2016 Annual General Meeting Nov 21 2016
Mesoblast widens losses on heart treatment Nov 14 2016
First Quarter Results Presentation Nov 14 2016
Mesoblast Provides Corporate Update and Q1 Financial Results Nov 14 2016
Successful Interim Futility Analysis In P3 Trial for GVHD Nov 13 2016
Appendix 4C - quarterly Oct 31 2016
Annual Report to shareholders Oct 21 2016
Notice of Annual General Meeting/Proxy Form Oct 21 2016
Appendix 4G And Corporate Governance Statement Oct 21 2016
Mesoblast Phase 2 Diabetic Kidney Disease Results Published Oct 05 2016
Change of Melbourne Registry Address Notification Sep 09 2016
Mesoblast Appoints Bill Burns As Vice Chairman Aug 31 2016
Preliminary Final Report (Including Appendix 4E) Aug 24 2016
Annual Financial Results Presentation Aug 24 2016
Mesoblast Reports on Annual and Fourth Quarter Results Aug 24 2016
Appendix 3B Aug 19 2016
MSB Strengthens US Patent Portfolio For Rheumatic Diseases Aug 16 2016
Mesoblast P2 Results Show Dose-Related Improvements In RA Aug 08 2016
Mesoblast cell treatment shows promise in rheumatoid arthritis -study Aug 08 2016
Mesoblast regains full rights to stem cell heart failure treatment Jun 13 2016
Investors' Radars Failed to Catch Mesoblast (MESO), Has Yours? Apr 14 2016

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)